Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380676 | 1.00 | TP53 (0.43) | TP53FPR2GPR119MAPTTHRB | |
| SCHEMBL381060 | 0.91 | TP53 (0.44) | TP53FPR2GPR119PTPN2PTPN1 | |
| SCHEMBL381061 | 0.91 | TP53 (0.44) | TP53FPR2GPR119PTPN2PTPN1 | |
| SCHEMBL13031201 | 0.90 | TP53 (0.53) | TP53FPR2GPR119PTPN2PTPN1 | |
| SCHEMBL380783 | 0.90 | TP53 (0.53) | TP53FPR2GPR119PTPN2PTPN1 | |
| SCHEMBL381028 | 0.90 | TP53 (0.46) | TP53FPR2GPR119PTPN2PTPN1 | |
| SCHEMBL381029 | 0.90 | TP53 (0.46) | TP53FPR2GPR119PTPN2PTPN1 | |
| SCHEMBL380635 | 0.88 | GPR119 (0.51) | TP53FPR2GPR119PTPN2PTPN1 | |
| SCHEMBL380636 | 0.88 | GPR119 (0.51) | TP53FPR2GPR119PTPN2PTPN1 | |
| SCHEMBL380664 | 0.87 | TP53 (0.44) | TP53FPR2GPR119MAPTPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049513-B1 | PIPERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7829582-B2 | Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | TP53 4717/4885FPR2 3330/4885GPR119 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.